Lantern Pharma Inc
LTRN2.640USD
+0.080+3.13%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
29.15MCap. mercado
PérdidaP/E TTM
Más Datos de Lantern Pharma Inc Compañía
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Información de Lantern Pharma Inc
Símbolo de cotizaciónLTRN
Nombre de la empresaLantern Pharma Inc
Fecha de salida a bolsaJun 11, 2020
Director ejecutivoSharma (Panna L)
Número de empleados24
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 11
Dirección1920 Mckinney Avenue
CiudadDALLAS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal75201
Teléfono19722771136
Sitio Webhttps://www.lanternpharma.com/
Símbolo de cotizaciónLTRN
Fecha de salida a bolsaJun 11, 2020
Director ejecutivoSharma (Panna L)
Ejecutivos de Lantern Pharma Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 31 de ene
Actualizado: sáb., 31 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
Otro
72.28%
Accionistas
Accionistas
Proporción
Bios Equity Partners, LP.
9.08%
Biological Mimetics, Inc
7.55%
Prophase Labs Inc
5.64%
The Vanguard Group, Inc.
3.43%
CM Management, LLC
2.01%
Otro
72.28%
Tipos de accionistas
Accionistas
Proporción
Corporation
13.19%
Venture Capital
9.08%
Investment Advisor
7.38%
Investment Advisor/Hedge Fund
2.08%
Hedge Fund
1.49%
Individual Investor
0.41%
Research Firm
0.09%
Otro
66.29%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
75
2.26M
20.24%
-397.59K
2025Q3
75
2.28M
21.15%
-484.54K
2025Q2
71
3.78M
35.06%
-589.53K
2025Q1
73
4.04M
37.50%
-292.34K
2024Q4
75
4.10M
38.06%
-404.66K
2024Q3
73
4.20M
39.03%
-539.55K
2024Q2
74
4.17M
38.76%
-357.16K
2024Q1
68
4.00M
36.90%
-906.94K
2023Q4
66
4.18M
38.50%
-1.07M
2023Q3
73
4.62M
42.50%
-2.30M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bios Equity Partners, LP.
1.02M
9.08%
-60.24K
-5.60%
Sep 30, 2025
Biological Mimetics, Inc
844.13K
7.55%
--
--
Jul 23, 2025
Prophase Labs Inc
631.20K
5.64%
--
--
Jul 23, 2025
The Vanguard Group, Inc.
384.04K
3.43%
+20.32K
+5.59%
Sep 30, 2025
CM Management, LLC
225.00K
2.01%
+25.00K
+12.50%
Sep 30, 2025
Renaissance Technologies LLC
100.10K
0.9%
+9.50K
+10.49%
Sep 30, 2025
Geode Capital Management, L.L.C.
92.08K
0.82%
+190.00
+0.21%
Sep 30, 2025
Voss Capital LLC
50.00K
0.45%
--
--
Sep 30, 2025
GWM Advisors LLC
47.28K
0.42%
-9.23K
-16.33%
Sep 30, 2025
Keyser (Donald Jeffrey PH.D)
45.76K
0.41%
--
--
Jul 23, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
